The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure

    Research output: Contribution to journalArticle

    10 Citations (Scopus)

    Abstract

    ACE inhibitors (ACEIs) have now been shown to improve symptoms and survival in patients with mild, moderate and severe chronic heart failure. Their mechanism of action is thought to be a combination of RAAS suppression and augmentation of bradykinin and prostaglandins. Although ACE inhibitors improve hemodynamics post myocardial infarction, we do not yet have consistent data on their effects on symptoms or survival in these particular patients. One other potential benefit is their effects on reperfusion injury and free radicals. As yet only minor differences have been found to exist between different ACEIs but increasing attention is now being focussed in this direction.
    Original languageEnglish
    Pages (from-to)187-197
    Number of pages11
    JournalPharmacology & Therapeutics
    Volume53
    Issue number2
    DOIs
    Publication statusPublished - 1992

    Fingerprint

    Clinical Pharmacology
    Angiotensin-Converting Enzyme Inhibitors
    Heart Failure
    Survival
    Bradykinin
    Reperfusion Injury
    Free Radicals
    Prostaglandins
    Hemodynamics
    Myocardial Infarction

    Cite this

    @article{8c4415341b844cf4a0eb8af011c799c2,
    title = "The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure",
    abstract = "ACE inhibitors (ACEIs) have now been shown to improve symptoms and survival in patients with mild, moderate and severe chronic heart failure. Their mechanism of action is thought to be a combination of RAAS suppression and augmentation of bradykinin and prostaglandins. Although ACE inhibitors improve hemodynamics post myocardial infarction, we do not yet have consistent data on their effects on symptoms or survival in these particular patients. One other potential benefit is their effects on reperfusion injury and free radicals. As yet only minor differences have been found to exist between different ACEIs but increasing attention is now being focussed in this direction.",
    author = "Struthers, {Allan D.}",
    year = "1992",
    doi = "10.1016/0163-7258(92)90008-N",
    language = "English",
    volume = "53",
    pages = "187--197",
    journal = "Pharmacology & Therapeutics",
    issn = "0163-7258",
    publisher = "Elsevier",
    number = "2",

    }

    The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure. / Struthers, Allan D.

    In: Pharmacology & Therapeutics, Vol. 53, No. 2, 1992, p. 187-197.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The clinical pharmacology of angiotensin converting enzyme inhibitors in chronic heart failure

    AU - Struthers, Allan D.

    PY - 1992

    Y1 - 1992

    N2 - ACE inhibitors (ACEIs) have now been shown to improve symptoms and survival in patients with mild, moderate and severe chronic heart failure. Their mechanism of action is thought to be a combination of RAAS suppression and augmentation of bradykinin and prostaglandins. Although ACE inhibitors improve hemodynamics post myocardial infarction, we do not yet have consistent data on their effects on symptoms or survival in these particular patients. One other potential benefit is their effects on reperfusion injury and free radicals. As yet only minor differences have been found to exist between different ACEIs but increasing attention is now being focussed in this direction.

    AB - ACE inhibitors (ACEIs) have now been shown to improve symptoms and survival in patients with mild, moderate and severe chronic heart failure. Their mechanism of action is thought to be a combination of RAAS suppression and augmentation of bradykinin and prostaglandins. Although ACE inhibitors improve hemodynamics post myocardial infarction, we do not yet have consistent data on their effects on symptoms or survival in these particular patients. One other potential benefit is their effects on reperfusion injury and free radicals. As yet only minor differences have been found to exist between different ACEIs but increasing attention is now being focussed in this direction.

    U2 - 10.1016/0163-7258(92)90008-N

    DO - 10.1016/0163-7258(92)90008-N

    M3 - Article

    C2 - 1641405

    VL - 53

    SP - 187

    EP - 197

    JO - Pharmacology & Therapeutics

    JF - Pharmacology & Therapeutics

    SN - 0163-7258

    IS - 2

    ER -